Associated Papers
Cross resistance to diverse anticancer nicotinamide phosphoribosyltransferase inhibitors induced by FK866 treatment.
Ogino Y et al.
Oncotarget, 2018
Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation.
Guo J et al.
Biochemical and Biophysical Research Communications, 2017
Structural basis for resistance to diverse classes of NAMPT inhibitors.
Wang W et al.
Plos One, 2014
Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
Olesen UH et al.
Bmc Cancer, 2010
Select a paper to view details